# A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting

> **NCT03604224** · — · COMPLETED · sponsor: **Johnson & Johnson Private Limited** · enrollment: 178 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canagliflozin 300 mg

## Key facts

- **NCT ID:** NCT03604224
- **Lead sponsor:** Johnson & Johnson Private Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-05
- **Primary completion:** 2019-07-01
- **Final completion:** 2019-07-01
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2020-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03604224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03604224, "A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03604224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*